Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1RN | P18510 | 1/20 | 0.33 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.33 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ESR1 | P03372 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847795 | 0.73 | MAPT (0.40) | NPC1MAPT | |
| SCHEMBL29054978 | 0.67 | GRIA1 (0.32) | IL1RNERAP2ERAP1 | |
| SCHEMBL8983390 | 0.66 | HTR2A (0.30) | — | |
| SCHEMBL5124908 | 0.66 | NR3C1 (0.30) | — | |
| SCHEMBL5111692 | 0.64 | PDE3B (0.34) | — | |
| SCHEMBL20572162 | 0.61 | GRIA1 (0.35) | ALDH1A1POLBKMT2A | |
| SCHEMBL5112202 | 0.61 | ABCC9 (0.34) | — | |
| SCHEMBL15464043 | 0.58 | NPC1 (0.36) | IL1RNERAP2ERAP1NPC1MAPT | |
| SCHEMBL5119353 | 0.58 | CA2 (0.35) | ALDH1A1CYP1A2CYP2C9CYP2C19KMT2A | |
| SCHEMBL21585257 | 0.58 | IL1RN (0.31) | IL1RNERAP2ERAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435733-B2 | Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NR3C2, MC2R, NR3C1 | IL1RN 692/4885ERAP2 1502/4885ERAP1 1929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.